Standout Papers

A Highly Durable RNAi Therapeutic Inhibitor of PCSK9 2016 2026 2019 2022 569
  1. A Highly Durable RNAi Therapeutic Inhibitor of PCSK9 (2016)
    Kevin Fitzgerald, Anna Borodovsky et al. New England Journal of Medicine

Immediate Impact

6 by Nobel laureates 10 from Science/Nature 73 standout
Sub-graph 1 of 23

Citing Papers

Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity
2025 Standout
Tirzepatide as Compared with Semaglutide for the Treatment of Obesity
2025 Standout
1 intermediate paper

Works of Ashley Brooks being referenced

Semaglutide improves postprandial glucose and lipid metabolism, and delays first‐hour gastric emptying in subjects with obesity
2017

Author Peers

Author Last Decade Papers Cites
Ashley Brooks 356 255 366 12 883
Gabriel P. Lasala 261 384 680 14 1.0k
Cara East 196 222 530 20 756
Douglas Logan 131 250 621 15 975
Hanny Wassef 246 124 614 17 860
Deshun Lu 307 62 307 23 1.1k
Francesca Charlton 160 199 429 13 750
Roland P.T. Troquay 217 132 531 6 769
Mercedes N. Munkonda 303 71 219 20 786
Maartje E. Visser 245 393 484 13 926
Michael Lillestol 289 133 530 8 1.0k

All Works

Loading papers...

Rankless by CCL
2026